An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients

Can J Psychiatry. 2009 Apr;54(4):269-74. doi: 10.1177/070674370905400408.

Abstract

Objective: Adverse effects from medication vary with age. Weight gain with several psychotropics is well known in adults but less information is available related to extent and complications of psychotropic-induced weight gain in older psychiatric patients. We determined the relative incidence of 2 obesity-related conditions (diabetes and hypertension) in older psychiatric patients receiving antipsychotics, antidepressants, and mood stabilizers.

Method: A population-based case-control study of all psychiatric patients aged 67 years or older in contact with either specialist services or primary care using administrative data from Nova Scotia.

Results: We identified incident cases of diabetes (n = 608) and of hypertension (n = 1056), as well as an equal number of control subjects for each condition. Amitryptiline, selective serotonin reuptake inhibitors (SSRIs), and olanzapine were associated with an increased risk of presenting with hypertension 6 months after initial prescription. By contrast, conventional antipsychotics were associated with a reduced incidence of hypertension. Olanzapine was also significantly associated with diabetes after 6 months (OR adj = 2.58, 95% CI 1.12 to 5.92). The findings for SSRIs and olanzapine remained significant after adjusting for potential confounders such as sociodemographic characteristics, schizophrenia, beta blockers, thiazide diuretics, and corticosteroids.

Conclusions: Our results suggest that the association of psychotropics and 2 obesity-related conditions, hypertension and diabetes, applies to older psychiatric patients as well as younger populations. Within drug classes, there are drugs that have a greater association than others, and this may be a factor when choosing a specific agent.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents / adverse effects
  • Benzodiazepines / adverse effects
  • Benzodiazepines / therapeutic use
  • Chronic Disease
  • Diabetes Mellitus, Type 2 / chemically induced
  • Female
  • Humans
  • Hypertension / chemically induced
  • Hypertension / epidemiology
  • Male
  • Mental Disorders / drug therapy*
  • Mental Disorders / epidemiology
  • Obesity / chemically induced*
  • Obesity / epidemiology
  • Olanzapine
  • Psychotropic Drugs / adverse effects*
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Selective Serotonin Reuptake Inhibitors / therapeutic use

Substances

  • Antidepressive Agents
  • Antipsychotic Agents
  • Psychotropic Drugs
  • Serotonin Uptake Inhibitors
  • Benzodiazepines
  • Olanzapine